Curating your CRISPR queries

What will the first CRISPR clinical trials look like? And if real therapies should result, what kinds of costs will we be looking at? Will insurers ever cover them? And what kinds of safety risks come with in vivo gene editing? 

STAT’s Sharon Begley and Adam Feuerstein hosted a webinar last week on all things CRISPR. Turns out, the questions were so plentiful that many were left unanswered. Well, fear not: Sharon and Adam picked some questions that might be important to a broader audience, and fleshed out their answers. 

Read more.